Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct;147(4):765-783.e4.
doi: 10.1053/j.gastro.2014.07.018. Epub 2014 Jul 18.

Cell death and cell death responses in liver disease: mechanisms and clinical relevance

Tom Luedde  1 , Neil Kaplowitz  2 , Robert F Schwabe  3
Affiliations
Review

Cell death and cell death responses in liver disease: mechanisms and clinical relevance

Tom Luedde et al. Gastroenterology. 2014 Oct.

Abstract

Hepatocellular death is present in almost all types of human liver disease and is used as a sensitive parameter for the detection of acute and chronic liver disease of viral, toxic, metabolic, or autoimmune origin. Clinical data and animal models suggest that hepatocyte death is the key trigger of liver disease progression, manifested by the subsequent development of inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma. Modes of hepatocellular death differ substantially between liver diseases. Different modes of cell death such as apoptosis, necrosis, and necroptosis trigger specific cell death responses and promote progression of liver disease through distinct mechanisms. In this review, we first discuss molecular mechanisms by which different modes of cell death, damage-associated molecular patterns, and specific cell death responses contribute to the development of liver disease. We then review the clinical relevance of cell death, focusing on biomarkers; the contribution of cell death to drug-induced, viral, and fatty liver disease and liver cancer; and evidence for cell death pathways as therapeutic targets.

Keywords: Alcoholic Liver Disease; Apoptosis; Caspases; Clinical Trial; DAMP; DILI; Hepatocellular Carcinoma; NASH; Necroptosis; Necrosis; Necrosome; RIP Kinases; RIP3; Viral Hepatitis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Figure 2
Figure 2
Figure 3
Figure 3
See this image and copyright information in PMC

References

    1. Fattovich G, Olivari N, Pasino M, et al. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut. 2008;57:84–90. - PubMed
    1. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686. - PubMed
    1. Tai DI, Lin SM, Sheen IS, et al. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotrans- ferase levels over time. Hepatology. 2009;49:1859–1867. - PubMed
    1. Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carci- noma in patients with low HBV load. Gastroenterology. 2012;142:1140–1149.e3. quiz e13–e14. - PubMed
    1. Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology. 2003;124:97–104. - PubMed

Publication types